The simulation results presented here demonstrate the potential of the adaptive CRT device with dynamic optimization of AV and VV intervals for improving cardiac output beyond the current non-adaptive ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Multiple societies covering cardiovascular medicine, electrophysiology, heart failure, and imaging have released updated appropriate use criteria (AUC) for various cardiac implantable electronic ...

Wearable electronic devices such as smart watches, worn by consumers to monitor their health, could interfere with the correct working of cardiac implantable electronic devices (CIEDs), posing serious ...

The heart is a finely tuned machine, pumping and squeezing to move blood through the body with a fresh supply of oxygen and nutrients. Electrical activity provides the spark to coordinate and activate ...

Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced Medtronic has issued a recall of its implantable cardioverter defibrillators and cardiac ...

Cardiologists at the University of Rochester Medical Center are launching a new study in an effort to improve the treatment of a very common form of heart disease in the Asian population. Called MADIT ...

TYRX, a company that commercializes implantable combination drug and device products for infection control, announced that the 1,000th patient has been enrolled in the Citadel & Centurion clinical ...

WASHINGTON, DC—The vast majority of patients who develop an infection related to a cardiac implanted electronic device (CIED) do not have the hardware extracted in a timely manner, and these patients ...

PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

DENVER--(BUSINESS WIRE)--Use of TYRX, Inc.’s AIGISRx ® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular ...